Drug Trial Radar · NCT04665700
A Study in Healthy Japanese Men to Test How Well Different Doses of BI 764198 Are Tolerated
Last checked: Nov 20, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Feb 6, 2021
Primary completion
Oct 16, 2021
Study completion Oct 16, 2021
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Dec 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 20 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objectives of this trial are to investigate safety and tolerability of BI 764198 in healthy male subjects following oral administration of single dose and multiple rising doses per day over 14 days. Secondary objectives are the exploration of pharmacokinetics (PK) of BI 764198 after single and multiple oral dosing.
Conditions
- Healthy
Interventions
BI 764198Drug
BI 764198
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage [%] of subjects with drug-related adverse eventsTime frame: Up to 34 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SOUSEIKAI Sumida Hospital
Tokyo, Sumida-ku, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.